• 제목/요약/키워드: Short-course chemotherapy

검색결과 16건 처리시간 0.02초

폐결핵에서 6개월 단기 항결핵 화학요법의 추구검사 (Follow-Up Study of 6-Month Short Course Chemotherapy for Pulmonary Tuberculosis with 2SKHRZ/4HRZ)

  • 고형기;강윤정;임성용;신종욱;최재선;유지훈;박인원;최병휘;허성호;서승천
    • Tuberculosis and Respiratory Diseases
    • /
    • 제43권6호
    • /
    • pp.852-861
    • /
    • 1996
  • 연구배경: 균음전율, 치료실패율 또는 치료종결 1년후의 재발율로써 효과가 입증된 6개월 항결핵 단기요법은 이제 우리나라에서 결핵치료의 표준처방으로 인정 받고 있다. 그러나 우리나라에서와 같이 초회 내성율이 높은 지역에서는 임상가들이 6개월에 치료를 종료하기에는 어려운 점이 많다. 이에 저자들은 기존의 6개월 단기요법에 pyrazinamide를 6개월 계속 사용하는 2S(K)HRZ/4HRZ 6개월 단기요법을 시작하여 효과, 부작용 및 4년까지의 재발율을 알아보고자 하였다. 방법: 1985 년 1월부터 1990년 1월까지 중앙대학교 의과대학 부속 용산병원 내과외래에서 활동성폐결핵으로 진단받은 150명을 대상으로 2S(K)HRZ/4HRZ의 6개월 단기요법을 설시한 결과, 다음과 같은 성적을 얻었다. 결과: 1) 치료기간중 중간탈락자는 68명이었다. 원인은 환자가 임의로 중단한 예가 36명 (24%)으로 제일 많았고 약제부작용이 15명(10%), 타원으로 전원된 환자가 9명(6%), 약제내성이 8명(5.3%)이었다. 2) 72명(48%)이 6개월 단기요법을 받았으며 10명(6.7%)이 8개월이상의 치료를 받았고 불규칙투약, 2제이상의 약제내성과 기관지내 결핵 등에 의해서였다. 3) 6개월 단기요법을 시행했던 72명에서 1년이상 59명(81.9%), 4년이상 32명(44.4%)이 추적조사 되었으며 2명(3.4%)이 1년이내에 재발하였고 4년째 1명이 재발하여 총 3명이 재발하였다. 4) 약제 부작용은 평가가 가능했던 134명중에서 82명(61.2%)이 있었으나 13명(9.7%)만이 처방을 수정했다. 부작용은 고요산혈증과 연관된 관절통이 제일 많았으며 과민성반응, 위장관장애, 간독성 등의 순이었다. 결론: 우리나라에서 2S(K)HRZ/4HRZ의 6개월 단기요법에도 조기탈락이 많으며 적지않은 재발율이었다. 우리나라와 같이 결핵균의 약제 내성율이 높은 지역에서는 치료중에 내성검사결과를 참고하거나 중간검사를 설시하여 판정에 신중을 기해야 할 것으로 샤료된다. 또한 pyrazinamide을 6개월간 사용하는 6개윌 단기항결핵요법의 효과는 좀더 연구가 필요하다고 사료된다.

  • PDF

Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial

  • Aghili, Mahdi;Khalili, Nastaran;Khalili, Neda;Babaei, Mohammad;Farhan, Farshid;Haddad, Peiman;Salarvand, Samaneh;Keshvari, Amir;Fazeli, Mohammad Sadegh;Mohammadi, Negin;Ghalehtaki, Reza
    • Radiation Oncology Journal
    • /
    • 제38권2호
    • /
    • pp.119-128
    • /
    • 2020
  • Purpose: Colorectal cancer is becoming an increasing concern in the middle-aged population of Iran. This study aimed to compare the preliminary results of short-course and long-course neoadjuvant chemoradiotherapy treatment for rectal cancer patients. Materials and Methods: In this clinical trial we recruited patients with rectal adenocarcinoma located from 5 cm to 15 cm above the anal verge. Patients in group I (short-course) received three-dimensional conformational radiotherapy with a dose of 25 Gy/5 fractions in 1 week plus concurrent XELOX regimen (capecitabine 625 mg/㎡ from day 1-5 twice daily and oxaliplatin 50 mg/㎡ on day 1 once daily). Patients in group II (long-course) received a total dose of 50-50.4 Gy/25-28 fractions for 5 to 5.5 weeks plus capecitabine 825 mg/㎡ twice daily. Both groups underwent consolidation chemotherapy followed by delayed surgery at least 8 weeks after radiotherapy completion. The pathological response was assessed with tumor regression grade. Results: In this preliminary report on complications and pathological response, 66 patients were randomized into two study groups. Mean duration of radiotherapy in the group II (long-course) was 5 ± 1 days (range, 5 to 8 days) and 38 ± 6 days (range, 30 to 58 days). The median follow-up was 18 months. Pathological complete response was achieved in 32.3% and 23.1% of patients in the shortcourse and long-course groups, respectively (p = 0.558). Overall, acute grade 3 or higher treatment-related toxicities occurred in 24.2% and 22.2% of patients in group I and II, respectively (p = 0.551). No acute grade 4 or 5 adverse events were observed in either group except one grade 4 hematologic toxicity that was seen in group II. Within one month of surgery, no significant difference was seen regarding grade ≥3 postoperative complications (p = 0.333). Conclusion: For patients with rectal cancer located at least 5 cm above the anal verge, short-course radiotherapy with concurrent and consolidation chemotherapy and delayed surgery is not different in terms of acute toxicity, postoperative morbidity, complete resection, and pathological response compared to long-course chemoradiotherapy.

결핵성 흉막염에서의 6개월 단기 치료 (6-Month Short-Course Chemotherapy for Tuberculous Pleural Effusion)

  • 김태형;김경아;임채만;이상도;고윤석;김우성;김동순;김원동
    • Tuberculosis and Respiratory Diseases
    • /
    • 제45권3호
    • /
    • pp.509-518
    • /
    • 1998
  • 연구배경: 폐결핵의 치료에서 6개월 단기치료의 효과는 이미 증명되었으나, 결핵성 흉막염의 치료에서 단기 치료의 효과에 대하여는 알려진 바 없다. 결핵성 흉막염 자체는 치료 없이도 호전되지만 5년 이내에 약 2/3에서 폐결핵이 발병하게 되므로 결핵성 흉막염 치료 후 장기적 경과 관찰을 해야 그 치료효과를 판정할 수 있다. 결핵의 유병율과 약제 내성율이 높은 국내에서의 결핵성 흉막염의 6개월 단기치료에 대하여 별도의 연구가 필요하므로, 6개월 단기치료(HRZE 2개월 + HRE 4 개월)의 유용성을 알아보기 위해 기존의 9개월 치료와 비교하였다. 대상 및 방법: 1989년 5월부터 1993년 5월까지 서울중앙병원에 결핵성 흉막염으로 입원한 357명 중에서 그 진단이 균검사 혹은 조직학적 소견에 의해 이루어진 238명을 대상으로 의무기록을 이용한 후향적 연구를 실시하였다. 결 과: 대상 238예 중 2 예에서는 기조사된 약제 약제 내성 결과에 의한 2차 약제가 처방되었으며, 치료도중 중도 탈락한 38예 및 폐외 결핵 동반 혹은 객담 검사상 증명된 약제 내성으로 장기 치료를 시행한 23예, 치료 도중 발생한 간독성으로 약제를 변경한 8예를 제외한 167예(70.2%)가 각각 6개월 (88예) 또는 9개월 (79예) 치료를 완료하였다. 6개월 및 9개월 치료군 167예 중 흉부 방사선 촬영 소견상 흉막염만 있었던 60예(35.9%)에서 객담도말 또는 배양 검사상 결핵균 양성인 경우가 6예(10.0%)였고, 비활동성 결핵 소견이 동반된 63예(37.7%)에서는 18예(28.6%), 활동성 폐결핵 소견이 동반된 44예(26.3%)에서는 24예(54.5%)에서 객담도말 또는 배양 검사상 결핵균 양성이었다. 6개월 치료군에서는 치료 후 69예(78.4%)에서 평균 23개월 추적 관찰하였으며, 1예(1.4%)에서 종결 후 폐결핵이 발생하였다. 9개월 치료 군에서는 치료 후 71예(89.8%)에서 평균 23개월 추적 관찰하였으며, 2예(2.5%)에서 치료 종결 후 폐결핵이 발생하였다. 치료 종결 후 폐결핵 발생 예는 모두 결핵성 흉막염의 진단 당시 활동성 폐결핵 소견을 보였다. 결 론: 결핵성 흉막염의 치료에서 6개월 단기 치료 후 폐결핵 발생율은 9개월 치료와 차이가 없었으며, 이상의 결과로 결핵성 흉막염에서 6개월 단기치료는 유용한 치료 방법으로 사료된다.

  • PDF

Short-course hypofractionated radiochemotherapy for unresectable locally advanced cancer of the base of tongue: palliation only? A case report and short review of the literature

  • Kalogeridi, Maria-Aggeliki;Kouloulias, Vassilios;Zygogianni, Anna;Kyrgias, George
    • Radiation Oncology Journal
    • /
    • 제32권2호
    • /
    • pp.99-102
    • /
    • 2014
  • We present a case of unresectable cancer of the base of tongue treated with hypofractionated 3D conformal radiotherapy and concomitant chemotherapy. Based on the excellent tumour response in this radiotherapy regimen and international experience in short course treatments we shortly reviewed, we propose that this therapeutic approach could be considered in a curative setting for patients unsuitable for the a standard long course radiochemotherapy schedule.

서울시 보건소에 등록된 폐결핵환자의 단기치료성적에 관한 연구 (A study on results of short-course chemotherapy of patients with pulmonary tuberculosis registered at Seoul city health centers)

  • 박혜숙;하은희;위자형
    • Journal of Preventive Medicine and Public Health
    • /
    • 제28권2호
    • /
    • pp.487-496
    • /
    • 1995
  • This study was performed for the comparison of the therapeutic efficiency between 6-month (2HERZ/4HER) and 9-month (9HER) short-course chemotherapy under the programe conditions for pulmonary tuberculosis in terms of sputum AFB negative conversion rate, remedial interruption rate and cost effectiveness analysis. Two hundreds and ninty three patients treated with 9HER and 641 treated with 2HERZ/4HER had been discharged from 22 health centers in Seoul from May 1, 1993 to April 30, 1994. Seven hundreds and seventeen was subsequently analysed excluding 217 patients due to remedial interruption. The results : 1. Bacteriological negative conversion rate in 9HER regimen and 2HERZ/4HER regimen was 97.8% and 96.4% respectively(p>0.05). But the early treatment period, negative conversion rate in 2HERZ/4HER regimen was very higher than in 9HER regimen(p<0.01). 2. Remedial interruption rate for 9HER regimen and 2HERZ/4HER regimen was 34.1% and 13.6% respectively. The primary reason for the interruption was transfering to other clinics and this interruption was high within 3months. 3. Cost effectiveness for 2HERZ/4HER regimen was higher than 9HER regimen. The difference cost effectiveness ratio was 2.33 at the first sputum test and 1.69 at the last sputum test.

  • PDF

Screening for Patients with Non-small Cell Lung Cancer Who Could Survive Long Term Chemotherapy

  • Wu, Xue-Yan;Huang, Xin-En
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제16권2호
    • /
    • pp.647-652
    • /
    • 2015
  • Background: Lung cancer was one of the most common cancers in both men and women all over the world. In this study, we aimed to clarify who could survive after long term chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Methods: We enrolled 186 patients with stage IV NSCLC after long term chemotherapy from Jun 2006 to Nov 2014 diagnosed in Jiangsu Cancer Hospital. Multiple variables like age, gender, smoking, histology of adenocarcinoma and squamous-cell cancer, number of metastatic sites, metastatic sites (e.g. lung, brain, bone, liver and pleura), hemoglobin, lymphocyte rate (LYR), Change of LYR during multiple therapies, hypertension, diabetes, chronic bronchitis, treatments (e.g.radiotherapy and targeted therapy) were selected. For consideration of factors influencing survival and response for patients with advanced NSCLC, logistic regression analysis and Cox regression analysis were used in an attempt to develop a screening module for patients with elevated survival after long term chemotherapy become possible. Results: Of the total of 186 patients enrolled, 69 survived less than 1 year (short-term group), 45 one to two years, and 72 longer than 3 years (long-term group). For logistic regression analysis, the short-term group was taken as control group and the long-term group as the case group. We found that age, histology of adenocarcinoma, metastatic site (e.g. lung and liver), treatments (e.g. targeted therapy and radiotherapy), LYR, a decreasing tendency of LYR and chronic bronchitis were individually associated with overall survival by Cox regression analysis. A multivariable Cox regression model showed that metastatic site (e.g. lung and liver), histology of adenocarcinoma, treatments (e.g. targeted therapy and radiotherapy) and chronic bronchitis were associated with overall survival. Thus metastatic site (e.g. lung and liver) and chronic bronchitis may be important risk factors for patients with advanced NSCLC. Gender, metastatic site (e.g. lung and liver), LYR and the decreasing tendency of LYR were significantly associated with long-term survival in the individual-variable logistic regression model (P<0.05). On multivariate logistic regression analysis, gender, metastatic site (e.g. lung and liver) and the decreasing tendency of LYR associated with long-term survival. Conclusions: In conclusion, female patients with stage IV adenocarcinoma of NSCLC who had decreasing tendency of LYR during the course therapy and had accepted multiple therapies e.g. more than third-line chemotherapy, radiotherapy and/or targeted therapy might be expected to live longer.

Preoperative short course radiotherapy with concurrent and consolidation chemotherapies followed by delayed surgery in locally advanced rectal cancer: preliminary results

  • Aghili, Mahdi;Sotoudeh, Sarvazad;Ghalehtaki, Reza;Babaei, Mohammad;Farazmand, Borna;Fazeli, Mohammad-Sadegh;Keshvari, Amir;Haddad, Peiman;Farhan, Farshid
    • Radiation Oncology Journal
    • /
    • 제36권1호
    • /
    • pp.17-24
    • /
    • 2018
  • Purpose: This study aimed to assess complications and outcomes of a new approach, that is, combining short course radiotherapy (SRT), concurrent and consolidative chemotherapies, and delayed surgery. Materials and Methods: In this single arm phase II prospective clinical trial, patients with T3-4 or N+ M0 rectal adenocarcinoma were enrolled. Patients who received induction chemotherapy or previous pelvic radiotherapy were excluded. Study protocol consisted of three-dimensional conformal SRT (25 Gy in 5 fractions in 1 week) with concurrent and consolidation chemotherapies including capecitabine and oxaliplatin. Total mesorectal excision was done at least 8 weeks after the last fraction of radiotherapy. Primary outcome was complete pathologic response and secondary outcomes were treatment related complications. Results: Thirty-three patients completed the planned preoperative chemoradiation and 26 of them underwent surgery (24 low anterior resection and 2 abdominoperineal resection). Acute proctitis grades 2 and 3 were seen in 11 (33.3%) and 7 (21.2%) patients, respectively. There were no grades 3 and 4 subacute hematologic and non-hematologic (genitourinary and peripheral neuropathy) toxicities and perioperative morbidities such as anastomose leakage. Grade 2 or higher late toxicities were observed among 29.6% of the patients. Complete pathologic response was achieved in 8 (30.8%) patients who underwent surgery. The 3-year overall survival and local control rates were 65% and 94%, respectively. Conclusion: This study showed that SRT combined with concurrent and consolidation chemotherapies followed by delayed surgery is not only feasible and tolerable without significant toxicity but also, associated with promising complete pathologic response rates.

6개월 단기 항결핵 화학요법의 성적 (Results of 6 Month Short Course Chemotherpay for Pulmonary Tuberculosis with 2SHRZ/4HR)

  • 이향주;민철홍;이선우;박인원;최병휘;허성호
    • Tuberculosis and Respiratory Diseases
    • /
    • 제38권2호
    • /
    • pp.93-98
    • /
    • 1991
  • A clinical trial was made on 76 patients with pulmonary tuberculosis to determine the effectiveness and acceptibility of 6 month 2SHRZ/4HR antituberculosis regimen. Out of 76 patients, 13 patients (17.1%) dropped out and 11 patients (14.5%) were excluded due to drug resistance. In 3 patients (3.9%), regimen was changed due to adverse effects. Treatment failure rate was 2.0% in 50 patients. One patient, who had far advanced lesion, was treated longer than 6 months due to failure of sputum conversion. The most common adverse effect was arthralgia, which was controlled by the administration of allopurinol and nonsteroidal anti-inflammatory drug. In conclusion, 2SHRZ/4HR for 6 months was effective regimen in treating the newly-diagnosed patients with tuberculosis, but change of the regimen and duration might be carefully considered by the severity of the lesion and adverse effect of the drug But further study will be needed to evaluate not only the efficacy and efficiency of 6 month chemotherapy but also relapse rates.

  • PDF

결핵성 경부 임파선염의 치료방법에 대한 전향적 연구 (Prospective Study for Treatment Method of Cervical Tuberculous Lymphadenitis)

  • 신경상;서재철;고동석;김근화;정성수;김주옥;김선영
    • Tuberculosis and Respiratory Diseases
    • /
    • 제45권3호
    • /
    • pp.503-508
    • /
    • 1998
  • 연구배경: 폐결핵은 점차 감소하는 추세이나 결핵성 림프선염은 그 빈도가 그대로 유지되고 있으며 우리나라에서는 그 치료약제 및 기간에 대해선 정립된 연구가 없었다. 이에 결핵성 경부 림프선염의 치료기간에 따른 치료결과를 전향적으로 비교하고자 하였다. 방 법: 1996년 3월부터 12월까지 충남대학교 병원에 내원하여 결핵성 경부 림프선염으로 진단받은 31명의 환자를 대상으로 무작위로 2HREZ/4HRE와 6HREZ의 2군으로 나누어 투약하면서 전향적으로 치료결과를 경과 관찰하였다. 결 과: 두군간의 나이와 성별비와 과거의 결핵약 복용유무에 있어서는 임상적인 차이는 없었으며 림프절의 수는 각각 $2{\pm}1.69$$3.4{\pm}1.98$이었으며 가장 큰 림프절의 평균크기는 $2.43{\pm}0.98cm$$3.15{\pm}1.74cm$로 통계학적인 의미는 없었다.(p>0.05) 치료후에 림프절의 크기로 치료결과를 비교하였을 때 각각 0.63cm와 0.6cm로 통계학적인 의미는 없었다.(p>0.05) 림프절이 커지거나 변하지 않아 지속적인 경과관찰이 필요한 경우는 2명이었다. 치료시 투여기간에 따른 부작용의 차이는 피부발진을 제외하고는 없었으며 어떤 부작용의 경우에도 투약을 중단할 정도로 심한 부작용이 있는 환자는 없었다. 결 론: 결핵성 림프선염은 젊은 여자에게서 호발하는 질병으로 경부 임파선염이 가장 흔하다. 결핵성 경부 림프선염은 전신적인 질환의 일부분으로 보고 항결핵 약제의 투여가 기본치료로 되어있으며 치료기간에 대해서는 장기간의 지속적인 투약이 필요하다는 보고가 있으나 6개월 표준요법으로도 충분히 치료되며 치료종결후 1년간의 추구관찰 결과 재발은 발견되지 않았다. 단 재발유무를 보기위해서는 좀 더 장기적인 추구관찰이 필요한 것으로 사료된다.

  • PDF

코의 Angiocentric Immunoproliferative Lesions(AILs) (Angiocentric Immunoproliferative Lesions(AILs) in Nose)

  • 한지연;김재유;이연수;정수미;김민식;윤세철;김훈교;조승호;김병기;이경식;김동집
    • 대한두경부종양학회지
    • /
    • 제12권1호
    • /
    • pp.16-21
    • /
    • 1996
  • Lymphomatoid granulomatosis, polymorphic reticulosis, midline malignant reticulosis, or lethal midline granuloma have similar histologic features of an angiocentric and angiodestructive lymphoreticular proliferation representing the same nosologic entity. The term 'angiocentric immunoproliferative lesion' (AIL) was proposed by Jaffe, Costa, and Martin. The malignant potential of AILs is originally uncertain, but the facts that AILs have a relatively short survival, and most of them usually progress to an overt malignant lymphoma and survival is inversely proportional to the large, atypical lymphoreticular cells suggest that AILs are malignane. We experienced 17 AILs in nose during 16-year period and retrogradely analized them to recognize the problems in the diagnosis and to establish the further therapeutic strategies. The results were as follows; Twelve of total 17 patients who had diagnosed as histologic grade 1 and 2 had received radiation therapy as an initial treatment and the complete response rate was 91.7%(11/12), but 6 out of 11 had local recurrence and 5 had progress to overt maligant lymphoma within 2years. Three patients with the histologic grade 3 and 2 with unclear histologic grade had received CHOP chemotherapy and there was 1 case with complete response. Two patients with unclear histologic grade had been proved to be malignant histiocytosis by bone marrow biopsy during the clinical course. The overall duration of survival was 2 - 119 months and the 5-year survival rate was 71.9%. And the achievement of initial complete response was the most important prognostic factor of overall survival(P=0.006). Our results suggest that the treatment strategy according to the histologic grading scheme is efficient and more aggressive combination chemotherapy may be necessary to achieve complete response in patients with histologic grade III and II, because most of them progress to overt malignant lymphoma during its process.

  • PDF